Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for diffuse large B cell lymphoma –second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Diffuse large B cell lymphoma is the most common type of non-Hodgkin's lymphoma. It can occur at any age but is more common in those over 65 years of age.
Nivolumab is a new antibody drug for the treatment of diffuse large B cell lymphoma and is delivered straight into the bloodstream via a drip. Some studies have suggested that this drug may be helpful for people with diffuse large B cell lymphoma whose disease has returned after the first treatment did not work. Another, larger study is now running and is aiming to find out how well nivolumab works and that it is safe to use.
If nivolumab is licenced for use in the UK, it could be a new treatment option for diffuse large B cell lymphoma that may improve survival when current treatments have stopped working. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Lymphoma, Large B-Cell, Diffuse Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000398 Date abstract record published 04/03/2016 |